BRAF and melanoma: Fitness penalties have been demonstrated in BRAF-resistant melanoma (29) and EGFR-resistant metastatic colorectal cancer (30) but have not been defined during the evolution of resistance to common cytotoxic therapies like platinum chemotherapy.